<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00872235</url>
  </required_header>
  <id_info>
    <org_study_id>CPU-M-024/QUINH-45/05</org_study_id>
    <nct_id>NCT00872235</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Quinapril Hydrochloride 20 mg and Hydrochlorothiazide 25 mg Tablets Under Fed Conditions</brief_title>
  <official_title>An Open Label, Balanced, Randomised, Two-Treatment, Four-Period, Two-Sequence, Single-Dose, Crossover, Fully Replicated Bioavailability Study on Fixed-Dose Combination of Quinapril 20 mg and Hydrochlorothiazide 25 mg Tablets of OHM Laboratories Inc.(Division of Ranbaxy Laboratories Limited) With Accuretic 20-25 mg Tablets (Fixed Dose Combination of Quinapril 20 mg and Hydrochlorothiazide 25 mg) of Parke-Davis (Division of Pfizer Inc.) in Healthy, Adult, Human, Male Subjects Under Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ranbaxy Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ranbaxy Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, balanced, randomized, two-treatment, four-period, two-sequence, single dose,&#xD;
      crossover fully replicated study was conducted on fixed-dose combination of quinapril 20 mg&#xD;
      and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc. (division of Ranbaxy&#xD;
      Laboratories Limited) and Accuretic 20-25 mg tablets of Parke-Davis (division of Pfizer Inc.)&#xD;
      in healthy, adult, human, male, subjects under fed conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The subjects received a single oral dose of either Test or Reference product, containing&#xD;
      fixed-dose combination of Quinapril 20 mg and Hydrochlorothiazide 25 mg after an overnight&#xD;
      fast of at least 10 hours. The study drug was administered as per the SAS generated&#xD;
      Randomization Code, 30 minutes after serving of a high-fat high-calorie breakfast under&#xD;
      supervision of a trained Medical Officer in each period.Blood samples were collected predose&#xD;
      and at intervals over 72 hours after each dose. A 7-day interval was maintained between each&#xD;
      dosing in the Study Periods I-IV.&#xD;
&#xD;
      During the course of the study safety parameters assessed were vital signs, physical&#xD;
      examination, medical history, clinical laboratory safety tests (hematology, biochemical&#xD;
      parameters and urine analysis) at base line. Laboratory parameters of hematology and&#xD;
      biochemistry were repeated and sodium &amp; potassium levels were estimated at the 24 hours post&#xD;
      dose of the last period of the study.&#xD;
&#xD;
      A total of 40 subjects were randomized to receive fixed-dose combination of quinapril 20 mg&#xD;
      and hydrochlorothiazide 25 mg tablets and 37 subjects completed all the four periods of the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <completion_date type="Actual">November 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence evaluation of Quinapril hydrochloride 20 mg and Hydrochlorothiazide 25 mg tablets under fed conditions</measure>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets of OHM Laboratories Inc.(division of Ranbaxy Laboratories Limited)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Accuretic tablets (fixed dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets</intervention_name>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be in the age range of 18-45 years.&#xD;
&#xD;
          2. Be neither overweight nor underweight for his/her height as per the Life Insurance&#xD;
             Corporation of India height/weight chart for non-medical cases.&#xD;
&#xD;
          3. Have voluntarily given written informed consent to participate in this study.&#xD;
&#xD;
          4. Be of normal health as determined by medical history and physical examination of the&#xD;
             subjects performed within 14 days prior to the commencement of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of allergy to quinapril, hydrochlorothiazide, sulfonamide derived drugs or&#xD;
             related ACE inhibitors.&#xD;
&#xD;
          2. History of anuria, gout or dry cough.&#xD;
&#xD;
          3. History of diarrhea or vomiting in the last one week.&#xD;
&#xD;
          4. Any evidence of organ dysfunction or any clinically significant deviation from the&#xD;
             normal, in physical or clinical determinations.&#xD;
&#xD;
          5. Presence of disease markers of HIV 1 or 2, Hepatitis B or C viruses or syphilis&#xD;
             infection.&#xD;
&#xD;
          6. Presence of values, which are significantly different from normal, reference ranges&#xD;
             (as defined in Appendix 5) and/or judged clinically significant for haemoglobin, total&#xD;
             white blood cells count, differential WBC count or platelet count.&#xD;
&#xD;
          7. Positive for urinary screen testing of drugs of abuse (opiates or cannabinoids).&#xD;
&#xD;
          8. Presence of values, which are significantly different from normal, reference ranges&#xD;
             (as defined in Appendix 5) and/or judged clinically significant for serum creatinine,&#xD;
             blood urea nitrogen, serum aspartate aminotransferase (AST), serum alanine&#xD;
             aminotransferase (ALT), serum alkaline phosphatase, serum bilirubin, plasma glucose or&#xD;
             serum cholesterol.&#xD;
&#xD;
          9. Clinically abnormal chemical and microscopic examination of urine defined as presence&#xD;
             of RBC, WBC (&gt;4/HPF), glucose (positive) or protein (positive).&#xD;
&#xD;
         10. Clinically abnormal ECG or Chest X-ray.&#xD;
&#xD;
         11. History of serious gastrointestinal, hepatic, renal, cardiovascular, pulmonary,&#xD;
             neurological or haematological disease, diabetes, glaucoma or angioedema due to any&#xD;
             cause.&#xD;
&#xD;
         12. History of any psychiatric illness which may impair the ability to provide written&#xD;
             informed consent.&#xD;
&#xD;
         13. Regular smokers who smoke more than 10 cigarettes daily or have difficulty abstaining&#xD;
             from smoking for the duration of each study period.&#xD;
&#xD;
         14. History of drug dependence or excessive alcohol intake on a habitual basis of more&#xD;
             than 2 units of alcoholic beverages per day (1 unit equivalent to half pint of beer or&#xD;
             1 glass of wine or 1 measure of spirit) or have difficulty in abstaining for the&#xD;
             duration of each study period.&#xD;
&#xD;
         15. Use of any enzyme modifying drugs within 30 days prior to Day 1 of this study.&#xD;
&#xD;
         16. Participation in any clinical trial within 12 weeks preceding Day 1 of this study.&#xD;
&#xD;
         17. A haemoglobin concentration of less than 7 % of lower limit of reference range e.g. 13&#xD;
             gm % for reference range of 14-18 gm at screening.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Ranbaxy CPU</name>
      <address>
        <city>New Delhi</city>
        <zip>110 062</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <link>
    <url>http://clinicalstudies.ranbaxy.com</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://dailymed.nlm.nih.gov/dailymed/about.cfm</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.fda.gov/opacom/7alerts.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2009</verification_date>
  <study_first_submitted>March 30, 2009</study_first_submitted>
  <study_first_submitted_qc>March 30, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 31, 2009</study_first_posted>
  <last_update_submitted>March 30, 2009</last_update_submitted>
  <last_update_submitted_qc>March 30, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Tausif Monif</name_title>
    <organization>Ranbaxy Research Labs</organization>
  </responsible_party>
  <keyword>Bioequivalence fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrochlorothiazide</mesh_term>
    <mesh_term>Quinapril</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

